drugset
drugset / Trial / NCT00030667

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

NCT00030667 ↗

Phase 2 Completed 100 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

Timeline

Start
2002-05
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule — Oral

Indications

Ewing sarcoma/peripheral primitive neuroectodermal tumor desmoplastic small round cell tumor gastrointestinal stromal tumor lung neoplasm neuroblastoma osteosarcoma synovial sarcoma